Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

View:
Post by HighteawithIntrepid on Nov 07, 2015 1:15pm

AdCom

The FDA's web page shows no conflict of
interest on the committee being declared.
Comment by DamnYankees on Nov 07, 2015 2:41pm
HT, has the makeup of the attendees been disclosed? I have not seen it if it has. I would be pleased to see Endo representation there on behalf of MCNA. Despite the history of the two companies Endo has the perfect structure and distribution profile to execute the go to market US launch of MCNA. I am not sure how many people here have been involved in an introduction of a pharma product into the ...more  
Comment by blartar on Nov 07, 2015 3:07pm
did TST not just hire an experienced marketing and sales infrastructure team ?.  Telesta Therapeutics Appoints Brian J. Groch as Chief Commercial Officer  As Chief Commercial Officer, Brian will be responsible for leading the development and execution of Telesta’s commercial strategy beginning with the U.S. commercial launch of MCNA1 for 2nd line high risk non-muscle invasive ...more  
Comment by DamnYankees on Nov 07, 2015 4:45pm
They have a guy. Singular. And are hiring some reps. For my money I'll take the ready made US distribution team over the start from scratch canadian option. But I know many people here are not Endo fans. It certainly looks like they are thinking of going it alone. It's a nice Poker chip in negotiations with your partner or buyer
Comment by greenbacks on Nov 07, 2015 5:15pm
Outsourcing the U.S. does not make good business sense. Otherwise TST is only a 100% royalty/licensing play and we might as well cash out now. As they will only get at most 20% of the 95% margin on a $400 B/year potential market. That is approx. 60-70M. x low multiple (4-6) as growth is limited in a royalty structure. My swag is 250-400 M in market cap.   Telesta will keep the U.S. market ...more  
Comment by HighteawithIntrepid on Nov 07, 2015 5:35pm
My SWAG: We will make a deal to licence Japan get a few more million up front and some milestone payments similar to the IPSEN deal. If a Japan deal is not done until after the 18th and we get a yes the upfront  payment will be larger and my guess is IPSEN will hand over some more cash ( a good question for the AGM). Don't forget Japan follows the FDA on most things. Then we have more ...more  
Comment by 13PunterDog on Nov 07, 2015 6:26pm
Agree with Greenback and you HT. We will get first line through the backdoor of second line approval. With the inevitable further manufacturing problems with BCG, doctors and patients will choose MCNA for first treatment. If MCNA can cure up to 35% of the patients who fail toxic BCG treatment , they will just go with it other  than wait for BCG. Remember, the MCNA trial was for refractory ...more  
Comment by cheetio on Nov 08, 2015 9:18am
doctors and patients will choose MCNA .........ya right...just like worldwide acceptance of ecoli vaccine......haahaa
Comment by cheetio on Nov 08, 2015 9:22am
.2008 Bioniche has begun a $25-million expansion at Dundas Street East and will be hiring at least 100 new workers over the next two years so it can produce 60 million to 80 million doses of the new vaccine annually to supply the international market.
Comment by cheetio on Nov 08, 2015 9:26am
acquired the $25 million needed for its expansion, including $10 million from the Ontario government and another $5-million federal government loan................
Comment by investderp on Nov 07, 2015 5:56pm
You want to bring someone from Endo to the AdCom meeting? You know AdCom means Advisory Committee, not Advertising Committee, right?
Comment by cheetio on Nov 08, 2015 8:30pm
did TST not just hire an experienced marketing and sales infrastructure team ?. .........yep Head of Market Access Payer and Trade Strategy Dendreon 2010 2013 (3 years)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities